Literature DB >> 15034931

Autocrine and paracrine nitric oxide regulate attachment of human osteoclasts.

Beatrice B Yaroslavskiy1, Yanan Li, David J P Ferguson, Sara E Kalla, Jennifer I Oakley, Harry C Blair.   

Abstract

Nitric oxide (NO) can reduce bone loss in chronic bone diseases. NO inhibits or kills osteoclasts, but the mechanism of action of NO in human bone turnover is not clear. To address this, we studied effects of NO on attachment and motility of human osteoclasts on mineralized and tissue culture substrates under defined conditions. Osteoclasts were differentiated in vitro from CD14 selected monocytes in RANKL and CSF-1, and characterized by cathepsin K expression, tartrate-resistant acid phosphatase (TRAP) activity, acid secretion, and lacunar resorption. Cell attachment was labeled with monoclonal antibody 23C6, specific for a binding domain of a key osteoclast attachment protein, the CD51/CD61 integrin dimer (alpha(v)beta(3)), with or without cell permeabilization. A ring of integrin attachment during bone degradation delimits an extracellular acid compartment, while alpha(v)beta(3) forms focal attachments on non-resorbable substrates. On resorbable substrate but not non-resorbable substrate, alpha(v)beta(3) labeling required cell permeabilization, in keeping with the membrane-matrix apposition that excludes large molecules and allows extracellular acidification. Acid secretion was labeled with the fluorescent weak base indicator lysotracker. NO donors, S-nitroso-N-acetyl penicillamine (SNAP) or sodium nitroprusside (SNP), downmodulated acid secretion simultaneously with cytoskeletal rearrangement, with alpha(v)beta(3) redistributed to a discontinuous pattern that labeled, on bone substrate, without membrane permeabilization. These effects were reversible, and an inhibitor of NO synthesis, N(G)-monomethyl-L-arginine (l-NMMA), increased acid secretion and decreased heterogeneity of attachment structures, showing that NO is an autocrine regulator of attachment. A hydrolysis-resistant activating cGMP analog 8-(4-chlorophenylthio)guanosine-3',5'-cyclic monophosphate replicated effects of NO donors, while an inhibiting analog, 8-(4-chlorophenylthio)guanosine-3',5'-cyclic monophosphorothioate, Rp-isomer, opposed them. On tissue culture or mineralized substrates, NO or cGMP analogs directly regulated motility; after washout cells reattached and survived for days. We conclude that NO is produced by human osteoclasts and regulates acid secretion and cellular motility, in keeping with autocrine and paracrine NO regulation of the resorption cycle. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034931     DOI: 10.1002/jcb.20009

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  12 in total

Review 1.  Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues.

Authors:  Scott P Nichols; Wesley L Storm; Ahyeon Koh; Mark H Schoenfisch
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

2.  A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.

Authors:  Hema Kalyanaraman; Ghania Ramdani; Jisha Joshua; Nadine Schall; Gerry R Boss; Esther Cory; Robert L Sah; Darren E Casteel; Renate B Pilz
Journal:  J Bone Miner Res       Date:  2016-09-07       Impact factor: 6.741

3.  Further evidence for direct pro-resorptive actions of FSH.

Authors:  Li Sun; Zhiyuan Zhang; Ling-Ling Zhu; Yuanzhen Peng; Xuan Liu; Jianhua Li; Manasi Agrawal; Lisa J Robinson; Jameel Iqbal; Harry C Blair; Mone Zaidi
Journal:  Biochem Biophys Res Commun       Date:  2010-02-19       Impact factor: 3.575

4.  Soluble guanylate cyclase as a novel treatment target for osteoporosis.

Authors:  Jisha Joshua; Gerburg K Schwaerzer; Hema Kalyanaraman; Esther Cory; Robert L Sah; Mofei Li; Florin Vaida; Gerry R Boss; Renate B Pilz
Journal:  Endocrinology       Date:  2014-09-04       Impact factor: 4.736

5.  Functional osteoclast attachment requires inositol-1,4,5-trisphosphate receptor-associated cGMP-dependent kinase substrate.

Authors:  Beatrice B Yaroslavskiy; Irina Turkova; Yujuan Wang; Lisa J Robinson; Harry C Blair
Journal:  Lab Invest       Date:  2010-06-21       Impact factor: 5.662

6.  Necessity of inositol (1,4,5)-trisphosphate receptor 1 and mu-calpain in NO-induced osteoclast motility.

Authors:  Beatrice B Yaroslavskiy; Allison C Sharrow; Alan Wells; Lisa J Robinson; Harry C Blair
Journal:  J Cell Sci       Date:  2007-08-15       Impact factor: 5.285

7.  YC-1 alleviates bone loss in ovariectomized rats by inhibiting bone resorption and inducing extrinsic apoptosis in osteoclasts.

Authors:  Jin-Wen Wang; Chin-Bin Yeh; Shao-Jiun Chou; Kuo-Cheng Lu; Tzu-Hui Chu; Wei-Yu Chen; Jui-Lin Chien; Mao-Hsiung Yen; Tien-Hua Chen; Jia-Fwu Shyu
Journal:  J Bone Miner Metab       Date:  2017-10-05       Impact factor: 2.626

Review 8.  Osteoclastic differentiation and function regulated by old and new pathways.

Authors:  Harry C Blair; Mone Zaidi
Journal:  Rev Endocr Metab Disord       Date:  2006-06       Impact factor: 9.306

9.  Osteopetrosis with micro-lacunar resorption because of defective integrin organization.

Authors:  Harry C Blair; Beatrice B Yaroslavskiy; Lisa J Robinson; Markus Y Mapara; Alessandra Pangrazio; Lida Guo; Ka Chen; Paolo Vezzoni; Jakub Tolar; Paul J Orchard
Journal:  Lab Invest       Date:  2009-06-22       Impact factor: 5.662

10.  ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone.

Authors:  Anna A Mourskaia; Eitan Amir; Zhifeng Dong; Kerstin Tiedemann; Sean Cory; Atilla Omeroglu; Nicholas Bertos; Véronique Ouellet; Mark Clemons; George L Scheffer; Morag Park; Michael Hallett; Svetlana V Komarova; Peter M Siegel
Journal:  Breast Cancer Res       Date:  2012-11-22       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.